These lawsuits are part of a group litigation called MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation, which represents people harmed by GLP-1 drugs
GLP-1: Addresses GLP-1 directly addresses the underlying mechanism GLP-1 does not meaningfully address this type GLP-1 medications directly address three of these five: inflammatory, metabolic, and neurological/traumatic
The FDA & compounding pharmacy telehealth connections on pop peptides like BPC-157, Ipamorelin, and more
This peak phase usually lasts 3 to 5 days before gradually improving as your body develops tolerance to the medication's effects
One reason Mounjaro remains expensive is that there is currently no FDA-approved generic version of tirzepatide available in the United States
At their September board meeting, Island Health officials listened to a presentation from Island Health doctor Dr